Qualigen Financial Statements From 2010 to 2024

Qualigen Therapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 1.9 M 2 M 13.9 M Pretty Stable Other Current Liabilities 583.9 K 614.6 K 2.2 M Slightly volatile Total Current Liabilities 5.4 M 4.1 M 3.7 M Slightly volatile Accounts Payable 2.3 M 2.2 M 1.1 M Slightly volatile Cash 381.7 K 401.8 K 11.6 M Slightly volatile Non Current Assets Total 823.2 K 866.5 K 1.2 M Slightly volatile Other Assets 0.95 1.0 13.7 K Very volatile Cash And Short Term Investments 381.7 K 401.8 K 11.6 M Slightly volatile Common Stock Total Equity 23.34 24.57 9.2 K Pretty Stable Common Stock Shares Outstanding 5.3 M 5.1 M 1.5 M Slightly volatile Liabilities And Stockholders Equity 1.9 M 2 M 14.7 M Pretty Stable Capital Surpluse 68.4 M 91.9 M 61.3 M Slightly volatile Other Current Assets 1.4 M 765 K 929.1 K Slightly volatile Other Stockholder Equity 81.5 M 114.7 M 63.8 M Slightly volatile Total Liabilities 5.9 M 4.1 M 4.1 M Slightly volatile Property Plant And Equipment Gross 7.8 M 7.4 M 1.8 M Slightly volatile Total Current Assets 1.1 M 1.2 M 12.8 M Slightly volatile Common Stock 40.3 K 43.3 K 27.5 K Slightly volatile Property Plant Equipment 1.3 M 2 M 859.4 K Slightly volatile Other Liabilities 491.2 K 467.8 K 147.2 K Slightly volatile Net Receivables 588.3 K 484.7 K 757.1 K Slightly volatile Inventory 1.1 M 1.8 M 1.1 M Pretty Stable Short Term Investments 5.6 M 6.3 M 6.8 M Slightly volatile Intangible Assets 7.1 M 6.7 M 1.6 M Slightly volatile Short and Long Term Debt Total 1.8 M 1.3 M 2 M Slightly volatile Current Deferred Revenue 167.4 K 104.5 K 295 K Slightly volatile Long Term Debt 244.6 K 275.2 K 299.7 K Slightly volatile Short and Long Term Debt 1.1 M 1.3 M 1.6 M Slightly volatile Capital Stock 66.5 K 43.3 K 156 K Slightly volatile Short Term Debt 691.6 K 1.3 M 1.5 M Slightly volatile
Qualigen Therapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Interest Income 86.2 K 141.5 K 79.5 K Slightly volatile Depreciation And Amortization 4.3 K 4.5 K 48.4 K Slightly volatile Selling General Administrative 7.3 M 6.1 M 6.6 M Slightly volatile Other Operating Expenses 17.6 M 11.3 M 20.2 M Very volatile Research Development 7.1 M 5.2 M 5.1 M Slightly volatile Cost Of Revenue 6.9 M 5.2 M 8.6 M Slightly volatile Total Operating Expenses 5.8 M 6.1 M 11.3 M Pretty Stable Selling And Marketing Expenses 4.3 K 4.5 K 379.5 K Very volatile Total Revenue 4.2 M 5.2 M 5.5 M Slightly volatile Reconciled Depreciation 4.3 K 4.5 K 210.4 K Pretty Stable
Qualigen Therapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Begin Period Cash Flow 10.7 M 7 M 7.3 M Slightly volatile Depreciation 4.3 K 4.5 K 84.6 K Slightly volatile Capital Expenditures 10.8 M 10.3 M 1.5 M Slightly volatile End Period Cash Flow 381.7 K 401.8 K 6.2 M Very volatile Stock Based Compensation 1 M 1.1 M 2.4 M Very volatile Dividends Paid 2.4 M 3.3 M 1.9 M Slightly volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 25.45 26.794 446 Pretty Stable Dividend Yield 0.0 0.0 0.0 Very volatile Days Sales Outstanding 31.03 47.78 43.9102 Very volatile Average Payables 1.1 M 1.3 M 1.4 M Slightly volatile Stock Based Compensation To Revenue 0.34 0.2111 0.2221 Slightly volatile Capex To Depreciation 1.86 0.98 1.4442 Very volatile EV To Sales 25.62 26.9665 445 Pretty Stable Inventory Turnover 2.96 3.12 5.535 Slightly volatile Days Of Inventory On Hand 127 121 73.753 Slightly volatile Payables Turnover 2.23 2.3434 5.6081 Very volatile Sales General And Administrative To Revenue 0.94 1.1712 0.7378 Slightly volatile Average Inventory 749.3 K 793.1 K 851.2 K Slightly volatile Research And Ddevelopement To Revenue 0.69 1.0009 0.5478 Slightly volatile Capex To Revenue 0.0605 0.0576 0.0358 Slightly volatile Cash Per Share 0.0753 0.0792 70.2679 Pretty Stable Days Payables Outstanding 112 156 92.8488 Pretty Stable Intangibles To Total Assets 0.32 0.31 0.1498 Pretty Stable Current Ratio 0.27 0.282 2.5242 Very volatile Receivables Turnover 7.51 7.91 14.23 Very volatile Graham Number 4.72 4.9693 250 Pretty Stable Capex Per Share 0.14 0.0956 0.1778 Slightly volatile Average Receivables 590 K 472.9 K 610.8 K Slightly volatile Revenue Per Share 0.98 1.0263 7.3658 Slightly volatile Interest Debt Per Share 0.53 0.5569 6.8523 Pretty Stable Debt To Assets 0.67 0.639 0.417 Slightly volatile Operating Cycle 78.56 121 103 Very volatile Days Of Payables Outstanding 112 156 92.8488 Pretty Stable Ebt Per Ebit 0.78 1.1039 1.0231 Very volatile Quick Ratio 0.27 0.282 2.4137 Very volatile Net Income Per E B T 0.81 1.0751 0.9931 Slightly volatile Cash Ratio 0.0923 0.0971 2.2015 Very volatile Days Of Inventory Outstanding 127 121 73.753 Slightly volatile Days Of Sales Outstanding 31.03 47.78 43.9102 Very volatile Fixed Asset Turnover 3.08 3.24 49.6756 Very volatile Debt Ratio 0.67 0.639 0.417 Slightly volatile Price Sales Ratio 25.45 26.794 446 Pretty Stable Asset Turnover 2.69 2.5598 1.2444 Very volatile
Qualigen Therapeutics Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 197.9 M 222.6 M 242.4 M Slightly volatile Enterprise Value 194.4 M 218.7 M 238.2 M Slightly volatile

Qualigen Fundamental Market Drivers

Qualigen Upcoming Events

About Qualigen Therapeutics Financial Statements

Pair Trading with Qualigen Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Qualigen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Qualigen Therapeutics will appreciate offsetting losses from the drop in the long position's value.When determining whether Qualigen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Qualigen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Qualigen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Qualigen Therapeutics Stock:

How To Invest In Qualigen Details

Is Qualigen Stock a good investment? Details

What is Qualigen Therapeutics' Net Worth? Details

Largest Biotechnology Companies View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details